Binding Site collaborates with Prof Sigurdur Kristinsson of the University of Iceland in his pivotal MGUS screening study for the forthcoming iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial.
The study will examine blood samples from approximately 140,000 adults over age 40 in Iceland for the earliest signs of myeloma. A cancer of the blood plasma cells that affects approximately 90,000 in the US, and more than 200,000 around the world, myeloma can go undiagnosed until the disease begins to seriously damage health.
The company has been a contributor to the study design, is crucial to its execution, and will lead the initial screening phase of the study from their state of the art facility in Birmingham, UK. They will be utilising the Freelite immunoassays together with automated electrophoresis testing equipment.
“iStopMM is at the heart of everything Binding Site has stood for since the launch of Freelite; we are delighted to support Prof Kristinsson and to continue our close collaborations with both he and Prof Ola Landgren from Memorial Sloane Kettering,” said Dr Stephen Harding, R&D Director, and one of the instigators of this study.
Freelite is a polyclonal antibody-based test, specifically designed by Binding Site to accurately and precisely measure monoclonal free light chains in blood. Free light chains are produced in a variety of haematological (blood) cancers including Multiple Myeloma.